ABCA1 and ABCG1 as potential therapeutic targets for the prevention of atherosclerosis

被引:122
作者
Matsuo, Michinori [1 ]
机构
[1] Kyoto Womens Univ, Fac Home Econ, Dept Food & Nutr, 35 Imakumanokitahiyoshicyo, Kyoto 6058501, Japan
关键词
ABC transporter protein; Atherosclerosis; Cholesterol; High-density lipoprotein; Reverse cholesterol transport; HIGH-DENSITY-LIPOPROTEIN; CASSETTE TRANSPORTER A1; DEPENDENT CHOLESTEROL EFFLUX; CORONARY ATHEROSCLEROSIS; ACCELERATES ATHEROSCLEROSIS; CELLULAR-LOCALIZATION; EXTRACELLULAR DOMAIN; PEST SEQUENCE; MASS EFFLUX; PPAR-ALPHA;
D O I
10.1016/j.jphs.2021.11.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Prevention of atherosclerosis is important because it is a risk factor for cardiovascular diseases globally. One of the causes of atherosclerosis is accumulation of cholesterol and triglycerides in peripheral cells. ATP-binding cassette protein A1 (ABCA1) and G1 (ABCG1) are important in eliminating excess cholesterol from cells including macrophages and forming high-density lipoprotein, which contributes to the prevention and regression of atherosclerosis. Enhanced cholesterol efflux activities of ABCA1 and ABCG1 are expected to prevent the progression of atherosclerosis. ABCA1 and ABCG1 are induced by the LXR/RXR pathway and regulated transcriptionally, post-transcriptionally, and post-translationally. Their mRNAs are destabilized by microRNAs and their cellular localization and degradation are regulated by other proteins and phosphorylation. Furthermore, ABCA1 and ABCG1 suppress the inflammatory responses of macrophages. These proteins are effective targets because their increased activities can suppress cholesterol accumulation and inflammation in macrophages. Moreover, ABCA1 and ABCG1 prevent amyloid b accumulation; therefore, their increased activity may prevent Alzheimer's disease. Because ABCA1 and ABCG1 are affected by transcriptional, post-transcriptional, and post-translational regulation, the regulatory factors involved could also serve as therapeutic targets. This review highlights that ABCA1 and ABCG1 could be potential therapeutic targets for preventing atherosclerosis by regulating their expression, degradation, and localization. (C) 2021 The Author. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.
引用
收藏
页码:197 / 203
页数:7
相关论文
共 106 条
[1]   Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux [J].
Akiyama, TE ;
Sakai, S ;
Lambert, G ;
Nicol, CJ ;
Matsusue, K ;
Pimprale, S ;
Lee, YH ;
Ricote, M ;
Glass, CK ;
Brewer, HB ;
Gonzalez, FJ .
MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (08) :2607-2619
[2]   Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption [J].
Altmann, SW ;
Davis, HR ;
Zhu, LJ ;
Yao, XR ;
Hoos, LM ;
Tetzloff, G ;
Iyer, SPN ;
Maguire, M ;
Golovko, A ;
Zeng, M ;
Wang, LQ ;
Murgolo, N ;
Graziano, MP .
SCIENCE, 2004, 303 (5661) :1201-1204
[3]   Helical apolipoproteins stabilize ATP-binding cassette transporter A1 by protecting it from thiol protease-mediated degradation [J].
Arakawa, R ;
Yokoyama, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (25) :22426-22429
[4]   Pharmacological inhibition of ABCA1 degradation increases HDL biogenesis and exhibits antiatherogenesis [J].
Arakawa, Reijiro ;
Tsujita, Maki ;
Iwamoto, Noriyuki ;
Ito-Ohsumi, Chisato ;
Lu, Rui ;
Wu, Chen-Ai ;
Shimizu, Kenji ;
Aotsuka, Tomoji ;
Kanazawa, Hashime ;
Abe-Dohmae, Sumiko ;
Yokoyama, Shinji .
JOURNAL OF LIPID RESEARCH, 2009, 50 (11) :2299-2305
[5]   MicroRNAs and lipid metabolism [J].
Aryal, Binod ;
Singh, Abhishek K. ;
Rotllan, Noemi ;
Price, Nathan ;
Fernandez-Hernando, Carlos .
CURRENT OPINION IN LIPIDOLOGY, 2017, 28 (03) :273-280
[6]   The COP9 signalosome controls ubiquitinylation of ABCA1 [J].
Azuma, Yuya ;
Takada, Mie ;
Maeda, Minami ;
Kioka, Noriyuki ;
Ueda, Kazumitsu .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2009, 382 (01) :145-148
[7]   Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[8]   Deletion of the transmembrane transporter ABCG1 results in progressive pulmonary lipidosis [J].
Baldan, Angel ;
Tarr, Paul ;
Vales, Charisse S. ;
Frank, Joy ;
Shimotake, Thomas K. ;
Hawgood, Sam ;
Edwards, Peter A. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (39) :29401-29410
[9]   Discovery of Nonlipogenic ABCA1 Inducing Compounds with Potential in Alzheimer's Disease and Type 2 Diabetes [J].
Ben Aissa, Manel ;
Lewandowski, Cutler T. ;
Ratia, Kiira M. ;
Lee, Sue H. ;
Layden, Brian T. ;
LaDu, Mary Jo ;
Thatcher, Gregory R. J. .
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE, 2021, 4 (01) :143-154
[10]   Coadministration of a liver X receptor agonist and a peroxisome proliferator activator receptor-α agonist in mice:: Effects of nuclear receptor interplay on high-density lipoprotein and triglyceride metabolism in vivo [J].
Beyer, TP ;
Schmidt, RJ ;
Foxworthy, P ;
Zhang, YY ;
Dai, JN ;
Bensch, WR ;
Kauffman, RF ;
Gao, H ;
Ryan, TP ;
Jiang, XC ;
Karathanasis, SK ;
Eacho, PI ;
Cao, GQ .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 309 (03) :861-868